By Julie A. Jacob | Special to Veterinary Practice News
Updated September 2026
Executive Overview
The landscape of companion animal veterinary medicine shifted significantly with the release of the American Animal Hospital Association’s (AAHA) updated diabetes management guidelines. Unveiled on September 6, these refreshed protocols represent a major departure from previous iterations—most notably the last comprehensive guidelines issued in 2018. For the first time in the association’s history, the framework has been bifurcated into entirely separate, highly focused documents: one dedicated exclusively to canines and the other to felines.
This structural overhaul was not merely cosmetic. Driven by an explosion of clinical research, novel pharmacological therapies, and a deeper understanding of the distinct pathophysiologies of canine versus feline diabetes mellitus, the AAHA expert task force spent years reviewing literature, debating clinical nuances, and synthesizing evidence-based recommendations. The resulting publications—AAHA Diabetes Management Guidelines for Dogs and AAHA Diabetes Management Guidelines for Cats—equip veterinary teams with modernized treatment algorithms, enhanced basal insulin options for dogs, targeted feline SGLT2 inhibitor selection criteria, and individualized nutrition paradigms.
By separating the documents, the AAHA has eliminated the compromises inherent in a one-size-fits-all approach. Clinicians can now instantly access granular, species-specific guidance designed to streamline decision-making, optimize glycemic control, and ultimately improve the quality of life for millions of diabetic pets and their caregivers.
Detailed Chronology: The Road to the 2026 Guidelines
The journey toward the 2026 guidelines began long before their official autumn release. Managing diabetes in companion animals has historically been fraught with clinical challenges, ranging from inconsistent owner compliance and unpredictable pharmacokinetic responses to the complex interplay of concurrent endocrinopathies.
The 2018 Baseline and the Accumulation of Clinical Data
When the AAHA released its prior iteration of diabetes management guidelines in 2018, the veterinary community praised them as a solid, unified foundation. However, veterinary endocrinology is a rapidly evolving discipline. In the years following the 2018 publication, a massive influx of clinical trials, pharmacokinetic studies, and retrospective evaluations entered the veterinary literature.
Researchers began exploring advanced insulin formulations long utilized in human medicine, testing their efficacy, safety profiles, and dosing mechanics in veterinary patients. Concurrently, a revolution was underway in feline diabetes management with the advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which changed how veterinarians approach blood glucose regulation in cats without relying solely on frequent insulin injections.
The Task Force Consensus Process
Recognizing that the volume of new data had outgrown the unified 2018 document, the AAHA convened a multidisciplinary expert task force. According to Andrew Bugbee, DVM, DACVIM (SAIM), co-chair of the AAHA Diabetes Management Guidelines for Dogs, the development process was exhaustive.
"There is a substantial amount of work put into the extensive literature reviews to identify new information, compile essential information to be incorporated into the guidelines, and several group sessions to discuss, debate, and ultimately reach a consensus about what recommendations go into the new documents," Dr. Bugbee explains.
He emphasizes that the guidelines are not merely academic exercises; rather, they represent a synthesis of empirical evidence and frontline clinical wisdom. "The guidelines reflect evidence-based information, varied clinical experience from several experts in the field, and group consensus on how to provide the most practical and clinically relevant recommendations for veterinary team members to use in their practices."
As discussions progressed, the task force realized that lumping dogs and cats into a single document was actively hindering the user experience. Canine diabetes is almost universally absolute insulin-dependent (type 1-like, typically driven by immune-mediated destruction or chronic pancreatitis), whereas feline diabetes frequently mirrors human type 2 diabetes, characterized by peripheral insulin resistance and impaired insulin secretion, with a distinct possibility of diabetic remission. These stark physiological divergences demanded a clean break.
Supporting Context & Metrics: Why Species Separation Matters
The decision to separate the guidelines into two distinct manuals marks a watershed moment in veterinary publishing. Renee Rucinsky, DVM, DABVP (Feline), and co-chair of the canine/feline task force framework, highlights the strategic advantage of this division.
"Due to the sheer amount of new, exciting, and clinically relevant information involving veterinary diabetes management that has come out over the past several years, this is the first time the AAHA Diabetes Management Guidelines have been separated by species," Dr. Rucinsky notes. "This enabled each document to more clearly present species-specific recommendations and allows readers to more quickly identify information needed to answer their questions about diabetic management."
Furthermore, Dr. Rucinsky points out that the administrative bifurcation "allowed the expert task force to really direct our conversations, literature searches, and recommendations in an even more focused way than the previous version of the guidelines."
The Canine Paradigm: Expanding the Therapeutic Toolbox
In the canine-focused document, the AAHA has introduced critical updates to treatment algorithms that reflect modern pharmacological advancements. Most notably, the 2026 guidelines formally incorporate basal insulin therapy as a primary tool for canine diabetes management.
Historically, canine diabetes management relied heavily on intermediate-acting insulins administered twice daily, which occasionally presented challenges in maintaining smooth, 24-hour glycemic control without inducing hypoglycemic nadirs. The updated guidelines expand the clinician’s arsenal by evaluating long-acting basal insulins.
"The guidelines cover how insulin degludec and insulin glargine U-300 work, what doses are appropriate to start dogs on, how to initially monitor and adjust insulin to achieve control, and how to troubleshoot some common issues that may be encountered clinically," Dr. Bugbee details.
In addition to pharmacotherapy, the canine guidelines place renewed emphasis on individualized nutritional management. The days of prescribing a generic, high-fiber diet to every diabetic dog are officially behind us.
"A patient’s nutrition plan should be specifically tailored to provide appropriate nutrient profiles to manage their diabetes while also considering other comorbidities or patient factors," says Dr. Bugbee. For instance, a dog presenting with concurrent hyperlipidemia, chronic kidney disease, or protein-losing enteropathy requires a vastly different dietary strategy than an otherwise healthy, overweight diabetic retriever.
The Feline Paradigm: Precision Patient Selection for SGLT2 Inhibitors
For cats, the 2026 guidelines address one of the most significant advancements in recent feline medicine: the incorporation and careful patient selection for SGLT2 inhibitors. While these oral medications have transformed feline care by offering a needle-free alternative for blood glucose regulation, they are not appropriate for every patient.
The updated feline guidelines establish rigorous criteria for patient selection, emphasizing the absolute necessity of screening for diabetic ketoacidosis (DKA), urinary tract health, and adequate endogenous insulin production. By laying out clear screening protocols, the guidelines help practitioners maximize therapeutic benefits while mitigating the risk of serious adverse events such as euglycemic DKA.
Official Statements and Expert Perspectives
The veterinary community has widely praised the release of the 2026 guidelines for their pragmatic design and clinical applicability. By bridging the gap between high-level academic endocrinology and everyday general practice, the AAHA has provided a vital lifeline for primary care veterinarians who manage the vast majority of diabetic pets.
Industry leaders emphasize that diabetes management is fundamentally a team sport. Successful outcomes rarely hinge on insulin choice alone; they require seamless communication between the veterinarian, veterinary technicians, and the pet owner. The new guidelines stress the importance of client education, structured home monitoring (including blood glucose curves and continuous glucose monitoring systems), and recognizing the subtle signs of glycemic instability before they escalate into medical emergencies.
To facilitate rapid absorption in busy clinical settings, the AAHA has released supplementary companion documents. The Guidelines at a Glance for Dogs and Guidelines at a Glance for Cats serve as concise, highly accessible quick-reference sheets that veterinary professionals can pin to clinic walls, store on digital tablets, or consult during rushed appointment windows.
Future Outlook: The Evolution of Companion Animal Endocrinology
As veterinary medicine marches further into the 21st century, the release of the 2026 AAHA Diabetes Management Guidelines sets a new benchmark for clinical consensus documents. The shift toward species-specific separation acknowledges that dogs and cats are metabolically distinct entities requiring tailored medical solutions.
Looking ahead, veterinary endocrinologists anticipate that continuous glucose monitoring (CGM) data integration, refined pharmacological agents, and personalized genetic profiling will continue to reshape diabetes care. The foundational framework laid down by the AAHA task force ensures that veterinary teams are well-equipped to navigate these upcoming innovations.
Ultimately, these guidelines represent a shared commitment to alleviating suffering, extending the bond between humans and their animal companions, and bringing gold-standard endocrinological care out of specialty hospitals and into everyday practice.
References
- AAHA Diabetes Management Guidelines for Dogs. American Animal Hospital Association. Published September 6, 2026. Link
- AAHA Diabetes Management Guidelines for Cats. American Animal Hospital Association. Published September 6, 2026. Link
- AAHA Diabetes Management Guidelines for Dogs: Guidelines at a Glance. American Animal Hospital Association. Published September 6, 2026. PDF Link
- AAHA Diabetes Management Guidelines for Cats: Guidelines at a Glance. American Animal Hospital Association. Published September 6, 2026. PDF Link
About the Author: Julie A. Jacob is an accomplished communications professional and veteran writer specializing in veterinary medicine and animal health. She resides in Wisconsin with her standard poodle.